Navidea Biopharmaceuticals is launching its lymphatic mapping radiopharmaceutical Lymphoseek in the U.S., the company announced today. Navidea has partnered with Cardinal Health to distribute the product to U.S. health care providers. "Commercialization of Lymphoseek in the U.S. marks a pivotal milestone for Navidea, and we are pleased to deliver this innovative diagnostic imaging agent to patients with breast cancer and melanoma," said Navidea President and CEO Dr. Mark Pykett. Lymphatic mapping helps trace the spread of cancer.
Published in Brief: